Nicolas Fischer - Hypera SA CEO

HYPE3 Stock  BRL 28.40  0.10  0.35%   

CEO

Mr. Nicolas Fischer serves as the Chief Executive Officer of Consumption Business Unit and a Member of the Executive Board of Hypermarcas SA since June 29 2012. He joined the Company in 2012. He has experience in cosmetics hygiene and beauty sectors having worked for 20 years in the industry. He spent 17 years in Latin America after having initiated his career in Germany. Prior to joining the Company he was CEO at BDF Nivea in Brazil for six years. Previously he acted as the President at Wella in Chile for four years. He also served at Procter Gamble as Wella Chief Marketing Officer for Mercosul. From 1996 to 2001 he was CFO at BDF Nivea in Brazil. He graduated in Business Administration from Technische Universitaet Berlin where he also gained a post graduate degree in 1992. since 2012.
Age 47
Tenure 12 years
Phone55 11 3627 4206
Webhttps://www.hyperapharma.com.br

Hypera SA Management Efficiency

The company has return on total asset (ROA) of 0.0686 % which means that it generated a profit of $0.0686 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1626 %, meaning that it generated $0.1626 on every $100 dollars invested by stockholders. Hypera SA's management efficiency ratios could be used to measure how well Hypera SA manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 6.85 B in total debt with debt to equity ratio (D/E) of 0.7, which is about average as compared to similar companies. Hypera SA has a current ratio of 1.89, which is within standard range for the sector. Debt can assist Hypera SA until it has trouble settling it off, either with new capital or with free cash flow. So, Hypera SA's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Hypera SA sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Hypera to invest in growth at high rates of return. When we think about Hypera SA's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 4 records

CEO Age

Helio RotenbergPositivo Tecnologia SA
50
Eduardo CamaraJHSF Participaes SA
N/A
Joseph NigriTecnisa SA
N/A
Sergio KariyaMills Estruturas e
49
It offers branded prescription products under the Mantecorp Farmasa, Episol, Predsim, Alivium, Lisador, Rinosoro, Celestamine, Maxsulid, Diprospan, Mioflex-A, and Addera D3 brands dermo-cosmetics products under the Mantecorp Skincare brands and consumer health products under the Apracur, Benegrip, Coristina d, Engov, Epocler, Estomazil, and other brands. Hypera S.A. was founded in 2001 and is headquartered in So Paulo, Brazil. HYPERA ON operates under Drug ManufacturersSpecialty Generic classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 8918 people. Hypera SA (HYPE3) is traded on Sao Paulo Exchange in Brazil and employs 9,000 people.

Management Performance

Hypera SA Leadership Team

Elected by the shareholders, the Hypera SA's board of directors comprises two types of representatives: Hypera SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hypera. The board's role is to monitor Hypera SA's management team and ensure that shareholders' interests are well served. Hypera SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hypera SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
Joao Queiroz, Chairman of the Board
Nicolas Fischer, CEO of Consumption Business Unit, Member of the Executive Board
Juliana Salem, Legal Officer
Luciana Fleischner, Member of the Board of Directors
Maria Lacerda, Independent Member of the Board of Directors
David Coury, Independent Member of the Board of Directors
Rafael Batista, Executive Officer
Adalmario Couto, Chief Financial Officer, Investor Relations Officer, Business Development Officer
Flair Carrilho, Independent Member of the Board of Directors
Hlio Segouras, Head Health
Jairo Loureiro, Independent Member of the Board of Directors
Mauricio Christovam, HR Officer
Armando Ferreira, Tax Officer, Member of the Executive Board
Bernardo Hernandez, Member of the Board of Directors
Martim Mattos, Chief Financial Officer, Chief Controllership Officer, Member of the Executive Board
Esteban Fomperosa, Member of the Board of Directors
Breno Oliveira, Investor Relations Officer, Member of the Executive Board
Marcelo Goncalves, Director
Luciana Queiroz, Member of the Board of Directors
Claudio Santos, Chief Executive Officer, Member of the Executive Board
Luca Mantegazza, Independent Member of the Board of Directors
David Neto, Independent Member of the Board of Directors
Luiz Violland, CEO of Medical Business Unit, Member of the Executive Board
Alvado Link, Member of the Board of Directors
Hugo Leal, Member of the Board of Directors
Joao Aguilar, Risks Officer
Nelson Mello, Institutional Relations Officer, Member of the Executive Board
Vivian Angiolucci, Chief Operating Officer, Member of the Executive Board
Carlos Scorsi, COO, Member of the Executive Board
Luiz Clavis, Commercial and Marketing Vice President

Hypera Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Hypera SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Hypera SA in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Hypera SA's short interest history, or implied volatility extrapolated from Hypera SA options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hypera SA. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.
Note that the Hypera SA information on this page should be used as a complementary analysis to other Hypera SA's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.

Complementary Tools for Hypera Stock analysis

When running Hypera SA's price analysis, check to measure Hypera SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hypera SA is operating at the current time. Most of Hypera SA's value examination focuses on studying past and present price action to predict the probability of Hypera SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hypera SA's price. Additionally, you may evaluate how the addition of Hypera SA to your portfolios can decrease your overall portfolio volatility.
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
CEOs Directory
Screen CEOs from public companies around the world
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Please note, there is a significant difference between Hypera SA's value and its price as these two are different measures arrived at by different means. Investors typically determine if Hypera SA is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hypera SA's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.